Pharmalot Ed Silverman STAT Plus: Pharmalittle: India regulator finds 5% of drug samples are substandard; EMA claims new clinical trial registry is fixed
Pharmalot Ed Silverman STAT Plus: Pharmalittle: HIV vaccine study is stopped early; Merck has a plan to combat carcinogen found in diabetes drugs
Pharmalot Ed Silverman STAT Plus: Major purchasers predict expensive new therapies will keep driving drug price hikes
Pharmalot Ed Silverman STAT Plus: Pfizer says it will widen access to hundreds of off-patent medicines in low-income countries
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Lilly and AbbVie exit U.K. drug-pricing program; J&J scales back Covid-19 vaccine production
Pharmalot Ed Silverman STAT Plus: Large health insurers lowered barriers to fair access to some drugs, analysis finds
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Pharma prioritizes biologics over pills due to drug-pricing law; former Takeda employee accused of creating fake consulting firm
Pharmalot Ed Silverman STAT Plus: California is the latest state to sue drugmakers and PBMs over insulin pricing
Pharmalot Ed Silverman STAT Plus: Pharmalittle: HHS readying details for Medicare drug-price negotiations; doctors urge FDA to hold expert meeting before approving Alzheimer’s drug
Pharmalot Ed Silverman STAT Plus: Physicians group urges FDA to convene expert panel before finally approving an Alzheimer’s drug
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Pfizer will not license generic Covid-19 pill in China; BioMarin signs outcomes-based deal in Germany for gene therapy
Pharmalot Ed Silverman Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug
Pharmalot Ed Silverman STAT Plus: FDA scolds Sun Pharmaceutical for serious quality control problems at a key plant in India
Pharmalot Ed Silverman STAT Plus: Pharmalittle: FDA increasingly pausing trials of experimental meds; FDA commish isn’t surprised by congressional report on Alzheimer’s drug
Pharmalot Ed Silverman STAT Plus: Moderna plans to follow in Pfizer’s footsteps, charge up to $130 for Covid-19 vaccine in U.S.
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Pediatricians recommend obesity drugs for children; as JPM starts, industry execs have a gloomy financing outlook
Pharmalot Ed Silverman STAT Plus: The FDA has approved a new Alzheimer’s drug, but wide access may depend on CMS easing restrictions
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Pfizer scaling back early-stage research into rare diseases; BioNTech and U.K. partner on cancer trials
Pharmalot Ed Silverman STAT Plus: Pharma’s ambitious antibiotic venture fund makes another investment
Pharmalot Ed Silverman STAT Plus: Pharmalittle: New report gives glimpse into safety of an Alzheimer’s drug; Walgreens looks to dispense an abortion pill
Pharmalot Ed Silverman STAT Plus: The pandemic exposed global gaps in access to medicines. Can a contentious approach to close them gain traction?
Pharmalot Eric Boodman and Ed Silverman STAT Plus: Walgreens to pursue certification to provide abortion pills in pharmacies
Pharmalot Ed Silverman STAT Plus: Pharmalittle: FDA rule change allows pharmacies to offer abortion pills; Medicare could have saved billions if inflationary rebate law existed
Pharmalot Ed Silverman STAT Plus: Medicare would have saved $3.7 billion on Part B drugs if inflationary rebates were around in a recent three-year period
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Pharma plans to raise U.S. drug prices in January; U.S. sues AmerisourceBergen over opioid crisis
Pharmalot Adam Feuerstein STAT Plus: Pharmalittle: FDA approves a Genentech blood-cancer drug; Sean Parker expands his immunotherapy research empire
Pharmalot Matthew Herper STAT Plus: Pharmalittle: Merck pays Chinese biotech $175 million for cancer drugs; who will make a gene therapy for very sick kids?